Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Peptide reported today that they sold off part of the drug business to Medivir of Switzerland for 6 million STG. I assume this was the protease inhibitor business. Given their portfolio of vaccines for rare diseases that affect millions of people worldwide, no wonder Deutches Bank upgraded the stock with a target price of 185p from its current price of 90p The upgrade was several weeks ago, and I was wondering was it for this new announcement? Peptide Therapeutics Group is based in Cambridge, England and is in partnership with Medeva of Switzerland, Aventis Pasteur, Pfizer Eli Lily, Novartis, Peptimmune, the Research Council and the University of Dundee. They are working on vaccines such as: Arilvax Yellow Fever Vaccine, Oral Typhoid, H.Pylori, C. difficile, Veterinary Allergy vaccine, Oral ETEC, Japanese Encephalitis, Oral H. Pylori, Tick-born encephalitis, Hepatitis C, Menegitis B, the West Nile Encephalitis that hit New York City in 1999 and Dengue Fever Vaccine. Dengue Fever infects 100,000,000 people every year and kills 24,000 children each year, mostly in central and South America where people can afford a vaccine.
It is PTE on the LSE
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.